A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

Recruiting now · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Myotonic Dystrophy Type 1 (DM1)

In brief

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.

Key facts

Study ID
NCT06185764
Run by
Vertex Pharmaceuticals Incorporated
People needed
52
Starts
2024-02-20
Expected to finish
2027-02-02
Last updated by the study team
2026-06-08

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.